The burgeoning popularity of semaglutide , initially for metabolic conditions, is creating significant buzz within the British Isles, prompting a notable shift in peptide trends. Obtaining these compounds remains a complex challenge , with NHS coverage currently limited and independent providers offering treatment at a premium . Concerns are being